New Mexico's medical psilocybin program is getting a friendlier rulebook before it ever opens. The New Mexico Department of Health has told the state's rulemaking hearing officer that it plans several significant changes to its proposed patient and provider rule, known as 7.35.3 NMAC, in response to what it called a substantial volume of public comments.
The changes are laid out in a 10-page response letter dated Nov. 9 from Deputy General Counsel Christopher D. Woodward to hearing officer Craig Erickson. They are proposed revisions, not a final rule, but they address nearly every major complaint raised by patients, veterans, clinicians and advocates during the comment period that closed with an Oct. 2 hearing in Santa Fe.
The biggest shift removes the "certifying clinician" role entirely. Under the original draft, patients would have needed an in-person examination within the previous six months from a separate clinician holding a New Mexico controlled-substance registration. Commenters said that setup would hurt rural residents, raise costs, fail people at the end of life and shut out veterans, because Veterans Affairs doctors are federal employees and cannot sign off on a Schedule I substance.
The department now proposes to let program practitioners handle entry themselves. Practitioners would attest that they completed a department screening tool and would refer patients to a medical provider when the screening flags risks, when the patient has not seen a provider in the past 12 months, or whenever the practitioner chooses. The department said this effectively ends the requirement that every exam be in person. The rule will also list conditions and medications that trigger extra review, and the certifying provider will no longer need a controlled-substance registration.
The department also plans to strike the requirement that healing centers and other approved locations obtain a statement from their landlord or property owner. Instead, applicants would attest that they own the property or understand the legal risk involved. Patients would likewise attest that they have been told about psilocybin's federal status. The department said removing landlord approval resolves concerns raised about Section 8 and other federally assisted housing.
Other proposed revisions include:
- Cutting the maximum patient enrollment processing time from 30 calendar days to 10 business days, and describing it as a simple enrollment rather than an application. - Changing group session staffing to one practitioner for every nine patients, plus at least one additional practitioner, facilitator or qualified student for every three patients, with the practitioner required only to be in the building. - Charging no state fees for permits, certificates or applications. - Requiring treatment records to be kept for at least five years.
The department declined some requests. It will not create a separate low-cost microdosing track, though it said the framework does not prohibit lower doses agreed on by practitioner and patient as long as sessions happen in approved settings. It also rejected letting clinicians grow and administer their own psilocybin, citing conflicts of interest, and kept practicum training hours unchanged.
Advocates who pushed for the changes welcomed the shift. Chris Peskuski, a Marine Corps veteran in Albuquerque who serves as a peer facilitator on the UNM Psychedelic-Assisted Therapy Research Program's psilocybin study for PTSD, credited New Mexicans who kept submitting comments for months.
Gov. Michelle Lujan Grisham signed the Medical Psilocybin Act in April 2025, making New Mexico the first state to create a psilocybin program through its legislature rather than a ballot measure. The department has said it aims to enroll the first patients by the end of December 2026. Unlike Colorado, New Mexico has not legalized psilocybin for general adult use, so the program is limited to enrolled patients with qualifying conditions, treated in approved settings. The department noted that it still cannot judge final affordability until providers set their prices, which it has no authority to cap.
The hearing officer will now weigh the record before the department finalizes the rule. Psilocybin remains a Schedule I controlled substance under federal law.